Dexmedetomidine Use for Sedation in Patients Submitted to Tracheal Surgery

CompletedOBSERVATIONAL
Enrollment

14

Participants

Timeline

Start Date

February 1, 2018

Primary Completion Date

August 31, 2018

Study Completion Date

August 31, 2018

Conditions
Postoperative Sedation
Interventions
DRUG

Dexmedetomidine

patients undergoing tracheal resection and reconstruction surgery were enrolled in this prospective observational pilot study to evaluate dexmedetomidine-based sedation after tracheal surgery in an Intensive Care Unit (ICU). Patients remain electively intubated with an uncuffed nasal endotracheal tube, awake and exhibit spontaneous breathing The neck was maintained in flexion through chin-to-chest sutures. Infusion of dexmedetomidine was started from a dosage of 0.7 μg kg-1 h-1 followed by dose titration to the target level of the sedation Richmond Agitation Sedation Scale, (RASS) score -1/-2 using a dose range of 0.2-1.4 μg kg-1 h-1.

Trial Locations (1)

Unknown

azienda ospedaliero universitaria Sant'Andrea, Roma

All Listed Sponsors
lead

University of Roma La Sapienza

OTHER

NCT03723538 - Dexmedetomidine Use for Sedation in Patients Submitted to Tracheal Surgery | Biotech Hunter | Biotech Hunter